Correction
7/30/2013

An item in Monday's BIO SmartBrief gave an incorrect ceiling for the possible future sales price related to an option by Celgene to buy Acetylon Pharmaceuticals. The deal could exceed $1.6 billion, contingent on certain milestones. SmartBrief regrets the error.

Related Summaries